Advertisement

How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective

  • Jia-qin Gu
  • Yun-peng Guo
  • Zheng JiaoEmail author
  • Jun-jie Ding
  • Guo-Fu LiEmail author
Review Article
  • 19 Downloads

Abstract

Delayed or missed doses are unavoidable in clinical practice and remain as a challenge that threatens a patient’s health and quality-of-life, especially in the pharmacotherapy of chronic disease treatment. Unfortunately, information or guidance concerning the management of delayed or missed doses is scarce, precluding clinicians or clinical pharmacologists from instructing patients in a precision dosing manner. It is therefore urgent to develop remedial strategies to inform patients of alternative dosing regimens in compensation for the loss of efficacy due to delayed or missed doses and minimize unintended clinical consequences. Studies aiming to establish remedial regimens have been conducted since the 1980s for oral contraceptives and antihypertensive agents, using the controlled substitution of placebos for active medications. However, it appeared to be unethical in many areas of pharmacotherapy due to deliberately discontinuing or restarting the medication. Alternatively, pharmacometric modeling and simulation offers an opportunity to investigate the effect of various non-adherence scenarios on pharmacokinetic profiles and establish the optimum remedial dosing regimen in a time-effective and systematical way. This review provides a general overview of procedures and strategies on how to develop remedial dosing regimens based on pharmacometric approaches through the scrutiny of case examples in the literature.

Notes

Compliance with Ethical Standards

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.81573505), and ‘Weak Discipline Construction Project’ (No. 2016ZB0301-01) of Shanghai Municipal Commission of Health and Family Planning. The funding organizations played no role in the preparation, review, or approval of the article.

Conflict of interest

The authors have no conflicts of interest that are directly relevant to the contents of this review article.

References

  1. 1.
    Andrew G, Libby R, Lloyd S. I’ve missed a dose; what should I do? Aust Prescr. 1998;44(2):77–87.Google Scholar
  2. 2.
    Howard J, Wildman K, Blain J, Wills S, Brown D. The importance of drug information from a patient perspective. J Admin Pharm. 1999;16(3):115–26.Google Scholar
  3. 3.
    Lyons RF, Rumore MM, Merola MR. An analysis of drug information desired by the patient (are patients being told everything they wish to know under OBRA ‘90?). J Clin Pharm Ther. 1996;21(4):221–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–5.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50(3):501–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Cerner Multum. Lamotrigine. 2019. https://www.drugs.com/mtm/lamotrigine.html. Accessed 26 July 2019.
  7. 7.
    Cerner Multum. Valproic acid. 2019. https://www.drugs.com/mtm/valproic-acid.html. Accessed 26 July 2019.
  8. 8.
    Cerner Multum. Levetiracetam. 2019. https://www.drugs.com/mtm/levetiracetam.html. Accessed 26 July 2019.
  9. 9.
    P Thornton. Phenytoin. 2019. https://www.drugs.com/mtm/phenytoin.html. Accessed 26 July 2019.
  10. 10.
    Cerner Multum. Tiagabine. 2019. https://www.drugs.com/mtm/tiagabine.html. Accessed 26 July 2019.
  11. 11.
    Cerner Multum. Ethosuximide. 2019. https://www.drugs.com/mtm/ethosuximide.html. Accessed 26 July 2019.
  12. 12.
    Guillebaud J. The forgotten pill and the paramount importance of the pill-free week. Br J Family Plann. 1987;12(4):35–43.Google Scholar
  13. 13.
    Smith SK, Kirkman RJ, Arce BB, McNeilly AS, Loudon NB, Baird DT. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception. 1986;34(5):513–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu EQ, Jiao Z, Wang CY, Ding JJ, Zhang XH. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. Epilepsy Behav. 2019;96:132–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang CC, Ding JJ, Jiao Z, Yu EQ, Zhu GX. Remedial dosing recommendations for valproic acid nonadherence patients with epilepsy. 2019. http://chinaxiv.org/abs/201907.00014. Accessed 26 July 2019.
  17. 17.
    Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharmacol Ther. 2000;67(4):331–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Wu JY, Yu G, Li GF. Model-informed approaches for alternative aripiprazole dosing regimens and missed dose management: towards better adherence to antipsychotic pharmacotherapy. Eur J Drug Metab Pharmacokinet. 2018;43(4):471–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Sheiner LB, Halkin H, Peck C, Rosenberg B, Melmon KL. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975;82(5):619–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Jelliffe RW. Computer assistance in digitalis dosage. Federation Proc. 1968;27:348.Google Scholar
  21. 21.
    Staab A, Rook E, Maliepaard M, Aarons L, Benson C. Modeling and simulation in clinical pharmacology and dose finding. CPT: Pharm Syst Pharm. 2013;2(2):e29.Google Scholar
  22. 22.
    Peck CC. Quantitative clinical pharmacology is transforming drug regulation. J Pharmacokinet Pharmacodyn. 2010;37(6):617–28.PubMedCrossRefGoogle Scholar
  23. 23.
    Ding J-J, Zhang Y-J, Jiao Z, Wang Y. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation. Acta Pharmacologica Sinica. 2012;33(11):1431–40.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Garnett WR, McLean AM, Zhang Y, Clausen S, Tulloch SJ. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin. 2003;19(6):519–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Dutta S, Reed RC. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. J Clin Pharm Ther. 2006;31(4):321–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Gidal BE, Majid O, Ferry J, Hussein Z, Yang H, Zhu J, et al. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies. Epilepsy Behav. 2014;35:6–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Brittain ST, Wheless JW. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Epilepsy Behav. 2015;52(Pt A):31–6.CrossRefGoogle Scholar
  28. 28.
    Sunkaraneni S, Blum D, Ludwig E, Chudasama V, Fiedler-Kelly J, Marvanova M, et al. population pharmacokinetic evaluation and missed-dose simulations for eslicarbazepine acetate monotherapy in patients with partial-onset seizures. Clin Pharmacol Drug Dev. 2018;7(3):287–97.PubMedCrossRefGoogle Scholar
  29. 29.
    Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38(3):191–204.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang ZB, Ji SM, Han Y, Zang LL, Wang YH, Lu W, et al. Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy. Eur J Clin Pharmacol. 2017;73(4):445–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Li GF, Zheng QS, Yu Y, Zhong W, Zhou HH, Qiu F, et al. Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated pharmacokinetics in young and elderly chinese adults. Clin Pharmacokinet. 2019;58(7):927–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Yu G, Zhou HH, Zheng QS, Li GF. Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. Eur J Clin Pharmacol. 2019;75(4):543–51.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Li GF, Yu G, Liu HX, Zheng QS. Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges. Clin Pharmacokinet. 2014;53(2):197–202.PubMedCrossRefGoogle Scholar
  35. 35.
    Saint-Marcoux F, Woillard JB, Monchaud C, Friedl J, Bocquentin F, Essig M, et al. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. Pharmacol Res. 2015;100:281–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs. 2017;31(4):273–88.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Duffull SB, Wright DF. What do we learn from repeated population analyses? Br J Clin Pharmacol. 2015;79(1):40–7.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Methaneethorn J. Population pharmacokinetic analyses of lithium: a systematic review. Eur J Drug Metab Pharmacokinet. 2018;43(1):25–34.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Ma YJ, Jiang DQ, Meng JX, Li MX, Zhao HH, Wang Y, et al. Theophylline: a review of population pharmacokinetic analyses. J Clin Pharm Ther. 2016;41(6):594–601.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities? J Clin Pharmacol. 2019;59(3):309–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Han K, Pillai VC, Venkataramanan R. Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J. 2013;15(4):901–12.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Bloomfield C, Staatz CE, Unwin S, Hennig S. Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients. Antimicrob Agents Chemother. 2016;60(6):3407–14.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Guo T, van Hest RM, Roggeveen LF, Fleuren LM, Thoral PJ, Bosman RJ, et al. External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients. Antimicrob Agents Chemother. 2019;63(5):e02543-18.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75(4):1068–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, Fernandez de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201–12.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Ge S, Beechinor R, Hornik C, F. Standing J, Zimmerman K, Cohen-Wolkowiez M et al. External evaluation of a gentamicin infant population pharmacokinetic model using data from a national electronic health record database. 2018. 62(9):AAC.00669-18.Google Scholar
  47. 47.
    Deng C, Liu T, Wu K, Wang S, Li L, Lu H, et al. Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients. J Clin Pharm Ther. 2013;38(6):480–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Zhao CY, Jiao Z, Mao JJ, Qiu XY. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81(5):891–907.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Mao JJ, Jiao Z, Yun HY, Zhao CY, Chen HC, Qiu XY, et al. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol. 2018;84(1):153–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Zhang HX, Sheng CC, Liu LS, Luo B, Fu Q, Zhao Q, et al. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus. Br J Clin Pharmacol. 2019;85(4):746–61.PubMedCrossRefGoogle Scholar
  51. 51.
    Wang DD, Chen X, Fu M, Zheng QS, Xu H, Li ZP. Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica. 2019.  https://doi.org/10.1080/00498254.2019.1631505 CrossRefPubMedGoogle Scholar
  52. 52.
    Sansom L. Australian pharmaceutical formulary and handbook. 17th ed. Canberra: Pharmaceutical Society of Australia; 2000.Google Scholar
  53. 53.
    Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J. 2008;10(4):537–51.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Toth L, Muszbek L, Komaromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model. 2013;40:99–109.PubMedCrossRefGoogle Scholar
  56. 56.
    Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69–86.PubMedCrossRefGoogle Scholar
  57. 57.
    Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Curr Med Res Opin. 2005;21(9):1363–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Chen C, Wright J, Gidal B, Messenheimer J. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Ther Drug Monit. 2013;35(2):188–93.PubMedCrossRefGoogle Scholar
  59. 59.
    Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 2018;43(4):461–9.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Samtani MN, Sheehan JJ, Fu DJ, Remmerie B, Sliwa JK, Alphs L. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clin Pharmacol. 2012;4:25–40.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Chew M, Ma G, Xie R, Bockbrader H, Chapel S, Marshall S. Population pharmacokinetics of pregabalin extended-release in healthy volunteers and patients with postherpetic neuralgia, fibromyalgia, and partial-onset seizures. J Clin Pharmacol. 2019;59(11):1527–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacyShanghai Chest Hospital, Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China
  2. 2.Huashan Hospital, Fudan UniversityShanghaiPeople’s Republic of China
  3. 3.China Pharmaceutical UniversityNanjingPeople’s Republic of China
  4. 4.World Wide Antimalarial Resistance Network, Centre for Tropical Medicine and Global Health, Nuffield Department of MedicineOxford UniversityOxfordUK
  5. 5.Institution of Drug Clinical TrialSubei People’s HospitalYangzhouPeople’s Republic of China

Personalised recommendations